

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

June 13, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
4033.3000 USU.S. NATIONAL PHASE OF
INTERNATIONAL APPLICATION NO.
PCT/GB2003/003236

FILING DATE

ASSIGNED UNITED STATES
APPLICATION NO.: 10/521,522

FIRST NAMED APPLICANT

CONFIRMATION NO.

GROUP

Andrew Powell

1639

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	MM-DD-YYYY ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
THW	AA	US-5,430,133	July 4, 1995	Piani, et al.
	AB	US-5,405,949	April 11, 1995	Ungarelli, et al.
	AC	US-5,543,403	August 6, 1996	Petitou, et al.
	AD	US-5,958,899	September 28, 1999	Zoppetti, et al.
	AE	US-4,717,719	January 5, 1988	Sportoletti, et al.
	AF	US-6,127,347	October 3, 2000	Holme, et al.
	AG	5,795,860	08-18-1998	Witt et al.
✓	AH	US 2001/0051349 A1	12-13-2001	Dukler et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	MM-DD-YYYY PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
THW	AL	EP 0380719	1990-AUG-08	AJORCA SA (AR) Domanico Ricardo Hugo, et al.	
	AM	EP 0 557 887 B1	12-17-1997	Lino Liverani et al.	
✓	AN	WO 01/40796 A3	06-07-2001	Thermo Hybaid GMBH et al.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

THW	AR	Kariya, Yutaka, et al., "Preparation of Completely 6-O-Desulfated Heparin and Its Ability to Enhance Activity of Basic Fibroblast Growth Factor," <i>J. Biol. Chem.</i> , 275(34): 25949-25958 (2000).
	AS	Yates, Edwin A., et al., "Evidence for a Heparin Derivative Containing an N-Sulfated Aziridine Ring that Retains High Anti-Factor Xa Activity," <i>Carbohydr. Res.</i> , 298:335-340 (1997).
	AT	M. Jaseja, et al., "Novel Regio- and Stereoselective Modifications of Heparin in Alkaline Solution. Nuclear Magnetic Resonance Spectroscopic Evidence," <i>Can. J. Chem.</i> , 67:1449-1456 (1989).
	AU	Guimond, S.E. and Turnball, J.E., "Fibroblast Growth Factor Receptor Signalling is Dictated by Specific Heparan Sulphate Saccharides," <i>Curr Biol.</i> , 9:1343-1346 (1999).
	AV	Irie, A., et al., "Specific Heparan Sulfate Structures Involved in Retinal Axon Targeting," <i>Development</i> , 129: 61-70 (2002).
✓	AW	Kreuger, J., et al., "Sequence Analysis of Heparan Sulfate Epitopes with Graded Affinities for Fibroblast Growth Factors 1 and 2," <i>J. Biol. Chem.</i> , 276(33): 30744-30752 (2001).

EXAMINER	T. D. M	DATE CONSIDERED	11/26/07
----------	---------	-----------------	----------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 4033.3000 US	U.S. NATIONAL PHASE OF INTERNATIONAL APPLICATION NO. PCT/GB2003/003236	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		FILING DATE	ASSIGNED UNITED STATES APPLICATION NO.: 10/521,522	
June 13, 2005 (Use several sheets if necessary)		FIRST NAMED APPLICANT Andrew Powell	CONFIRMATION NO.	GROUP 1639

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
T.D.	AX	Nadkarni, V.D. and Linhardt, R.J., "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates," <i>Biotechniques</i> , 23:382-385 (1997).		
↓	AY	Nadkarni, V.D., <i>et al.</i> , "Directional Immobilization of Heparin onto Beaded Supports," <i>Anal Biochem</i> , 222: 59-67 (1994).		
↑	AZ	Yates, Edwin A., <i>et al.</i> , "H and C NMR Spectral Assignments of the Major Sequences of Twelve Systemically Modified Heparin Derivatives," <i>Carbohydrate Research</i> , 294: 15-27 (1996).		
↓	AR2	Dove, Alan, "The Bittersweet Promise of Glycobiology," <i>Nature Biotechnology</i> , 19: 913-917 (2001).		
↓	AS2	Database Biosis, Biosciences Information Service, Philadelphia, PA, US. Wu, Zhengliang L., <i>et al.</i> , "A New Strategy for Defining Critical Functional Groups on Heparan Sulfate," <i>FASEB J.</i> , 16(6), XP002268531 abstract (2002).		

EXAMINER T.D. M	DATE CONSIDERED 11/26/07
--------------------	-----------------------------